IntegraGen Reports Sharp Increase in Sales During 2016
January 09 2017 - 11:58AM
Business Wire
- Strong growth in revenue (+8%)
linked to the development of partnerships in very high-speed
sequencing with Institut Pasteur and Gustave Roussy and consulting
services provided by GeCo (Genomic Consulting)
2017 Outlook: major achievements
- Launch of the beta version of the
ICE software, dedicated to the clinical interpretation of
high-throughput sequencing data from exomes and transcriptomes of
cancer patients
- Launch of the production of the
mirPredX 31-3p test which is predictive of the response to
anti-EGFR therapy for patients with metastatic colorectal
cancer
Regulatory News:
IntegraGen (Paris:ALINT) (FR0010908723 – ALINT – Eligible PEA
PME), a company specializing in the decoding of the human
genome and performing interpretable genomic analyses for academic
and private laboratories and a developer of diagnostic tools in
oncology, today announced its unaudited revenue for 2016.
in millions of euros
2016 2015
2016
vs. 2015
Sales revenue 6,022 5,593 +8 %
The growth in annual revenue for 2016 was 8% compared to full
year 2015 results. These results demonstrate the robustness of
IntegraGen's business in genomics, driven by "clinical research"
and consulting activities. Services remained stable for the R &
D segment of the company’s business during 2016. After a strong
first half (+ 10%), linked in part to the sales generated by the
platform at the Institut Pasteur site which was initiated in March
2015, genomic activities continued to grow during the second half
of the year achieving a historical high in terms of the total level
of activity.
In addition, the growth in orders in 2016 was higher than
revenues, making it possible to anticipate sustained activity in
2017.
The company is also announcing the beta test of the ICE
(Interpretation of Clinical Exome) software developed jointly with
Sogeti High Tech, Gustave Roussy and INSERM beginning January 2017
which will involve user tests of the first version of this clinical
genomics data interpretation tool. The ICE software tool will
enable clinicians to refer cancer patients to appropriate
innovative therapeutic strategies (especially for new molecules in
Phase I or II clinical trials) with a high probability of success,
based on specific genomic characteristics of the patient’s
tumor.
In the area of diagnostics, the company initiated a project in
2016 to produce a predictive diagnostic kit for the response to
anti-EGFR treatments for patients with metastatic colorectal
cancer. The kit will be marketed in the European Union beginning
the second half of 2017.
Bernard Courtieu, Chairman and CEO said, "IntegraGen
continue to demonstrate strong growth with the company’s genomics
services business, which experienced an organic growth of 8% during
2016, and is actively working to develop other growth drivers.
Several strategic achievements are expected in 2017 including the
completion of beta testing for the ICE (Interpretation of Clinical
Exome) software, which targets a potential market of more than $ 4
billion*, and the planned launch of the miRpredX test, a predictive
diagnostic kit for oncology. We are approaching this new year with
enthusiasm and confidence."
* source BCC research
IntegraGen is a company specializing in deciphering the human
genome and producing relevant and easily interpretable data for
academic and private laboratories. IntegraGen’s oncology efforts
provide researchers and clinicians with sophisticated tools for
analysis and therapeutic individualization of treatment approaches
allowing them to tailor therapy to the genetic profiles of
patients. As of December 31, 2015, IntegraGen had 37 employees and
had generated revenue of €5.6 million in 2015. Based in Evry
Genopole, IntegraGen also has an U.S. office in Cambridge,
Massachusetts. IntegraGen is listed on Alternext of Euronext Paris
(ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).
For more information on IntegraGen visit www.integragen.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170109006043/en/
INTEGRAGENBernard COURTIEUPresident and CEOLaurence RIOT
LAMOTTEChief Financial OfficerTel: +33 (0)1 60 91 09
00contact@integragen.comorNewCapInvestors relationsEmmanuel
HUYNHLouis-Victor DELOUVRIERTel.: +33 (0)1 44 71 98
53integragen@newcap.eu
Integragen (EU:ALINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Integragen (EU:ALINT)
Historical Stock Chart
From Jul 2023 to Jul 2024